Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) (COVID+PA)

Abderrahmane Mami Hospital

Status and phase: Withdrawn; Phase 4

Conditions: Patients With COVID19

Treatments: Drug: Azithromycin; Drug: Hydroxychloroquine

Study type: Interventional

Funder types: Other; NETWORK

Identifiers

NCT04351919

ECC2020-04

Details and patient eligibility

About

The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed COVID19 (+)
• Qt<500ms
• no severity criteria
• pauci-symptomatique patients
• signed consent form

Exclusion criteria

• no confirmed patient COVID19
• severity criteria
• known allegies to macrolides and HCQ
• Treated with HCQ within 1 month prior to inclusion
• hepatitis insufficiency
• Renal insufficiency
• treatment no indicated with azithro and HCQ
• hypovolemia
• complete brach block
• retinopathia
• psoriasis
• pregnancy or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

HCQ Arm

Experimental group

Treatment:

Drug: Azithromycin

Drug: Hydroxychloroquine